Quick Notes: May 21, 2020

  • Oculis reports positive top-line data from its Phase 2 SKYGGN trial of OCS-01, a preservative-free, topical SNP formulation of dexamethasone (ophthalmic suspension 1.5%). The objective of SKYGGN study was to assess the efficacy and safety of OCS-01 applied once daily to treat inflammation and pain following cataract surgery. The study met both of its primary endpoints for inflammation and pain treatment. 

  • Care Access Vision is sponsoring DAWESTalk, a series of weekly eyecare industry discussions . Hosted by James Dawes and featuring guests from the ophthalmic industry, the next DAWESTalk on May 27 at 8:30 p.m. EST will be titled “A New Standard for the Patient Experience Post COVID-19.” To register, visit the DAWESTalk website

  • Maculogix and MPR were awarded the A’Design Platinum Award for the AdaptDx Pro medical headset. The A’Design Awards recognize achievements in design practices and principles for products, projects and services. The AdaptDx Pro, the successor to the AdaptDx, performs a non-invasive test that can identify and monitor AMD in patients with the help of Theia, an AI “technician.”

Quick Notes is published weekly. Unless otherwise noted, the information presented is based on press releases. Find earlier editions here. To submit a press release to be considered for publication, click here